

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Rafehi, H;Szmulewicz, DJ;Pope, K;Wallis, M;Christodoulou, J;White, SM;Delatycki, MB;Lockhart, PJ;Bahlo, M

Title:

Rapid Diagnosis of Spinocerebellar Ataxia 36 in a Three-Generation Family Using Short-Read Whole-Genome Sequencing Data

Date:

2020-09-01

Citation:

Rafehi, H., Szmulewicz, D. J., Pope, K., Wallis, M., Christodoulou, J., White, S. M., Delatycki, M. B., Lockhart, P. J. & Bahlo, M. (2020). Rapid Diagnosis of Spinocerebellar Ataxia 36 in a Three-Generation Family Using Short-Read Whole-Genome Sequencing Data. *Movement Disorders*, 35 (9), pp.1675-1679. <https://doi.org/10.1002/mds.28105>.

Persistent Link:

<https://hdl.handle.net/11343/275751>

Rapid diagnosis of SCA36 in a three-generation family using short-read whole genome sequencing data

Haloom Rafehi PhD^{1,2,3}, David J. Szmulewicz MBBS FRACP PhD^{4,5}, Kate Pope BSc Grad Dip Gen Couns⁶, Mathew Wallis BSc MBBS FRACP^{7,8}, John Christodoulou MBBS FRACP PhD^{9,10}, Susan M White MBBS FRACP^{10,11,12}, Martin B Delatycki MBBS FRACP PhD^{6,10,11}, Paul J Lockhart PhD^{6,10}, Melanie Bahlo PhD^{*1,2}

1. Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
2. Department of Medical Biology, University of Melbourne, Melbourne, Australia
3. Epilepsy Research Centre, University of Melbourne, Austin Health, Melbourne, Australia
4. Cerebellar Ataxia Clinic, Neuroscience Department, Alfred Health, Melbourne, VIC 3004, Australia;
5. Balance Disorders and Ataxia Service, Royal Victorian Eye & Ear Hospital, East Melbourne, VIC 3002, Australia
6. Bruce Lefroy Centre for Genetic Health Research, Murdoch Children's Research Institute, 50 Flemington Road Parkville, Victoria, 3052, Australia
7. Tasmanian Clinical Genetics Service, Tasmanian Health Service, Tasmania, Australia
8. School of Medicine and Menzies Institute for Medical Research, University of Tasmania, Tasmania, Australia
9. Brain and Mitochondrial Research Group, Murdoch Children's Research Institute, 50 Flemington Road Parkville, Victoria, 3052, Australia
10. Department of Pediatrics, The University of Melbourne, 30 Royal Parade Parkville, Victoria, 3052, Australia
11. Victorian Clinical Genetics Services, 50 Flemington Road Parkville, Victoria, 3052, Australia
12. Murdoch Children's Research Institute, 50 Flemington Road Parkville, Victoria, 3052, Australia

*Corresponding author:

Prof. Melanie Bahlo
The Walter and Eliza Hall Institute of Medical Research
1G Royal Parade, Parkville
Victoria 3052
Australia
bahlo@wehi.edu.au

Word count (main text): 1736.

Running title: SCA36 diagnosis by whole genome sequencing

Keywords: ataxia, repeat expansions, short tandem repeats, diagnosis, exSTRa

Financial disclosure/conflicts of interest: Nothing to report.

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/mds.28105](https://doi.org/10.1002/mds.28105)

Funding sources for study: The funding bodies had no role in the design, analysis, interpretation or reporting of results.

Abstract

Background: Spinocerebellar ataxias (SCA) are often caused by expansions of short tandem repeats (STRs). Recent methodological advances have made repeat expansion (RE) detection with whole genome sequencing (WGS) feasible.

Objectives: To determine the genetic basis of ataxia in a multigenerational Australian pedigree, with autosomal dominant inheritance.

Methods and Results: WGS was performed on three affected relatives. The sequence data was screened for known pathogenic REs using two repeat expansion detection tools: exSTRa and ExpansionHunter. This screen provided a clear and rapid diagnosis (<five days from receiving the sequencing data) of SCA36, a rare form of ataxia caused by an intronic GGCCTG RE in *NOP56*.

Conclusions: The diagnosis of rare ataxias caused by REs is highly feasible and cost effective with WGS. We propose that WGS could potentially be implemented as the frontline, cost effective methodology for molecular testing of individuals with a clinical diagnosis of ataxia.

Introduction

Spinocerebellar ataxias (SCA) comprise a group of rare, progressive neurological disorders that can be caused by deleterious coding-sequence point mutations or pathogenic expansions of short tandem repeats (STRs). Ataxias caused by repeat expansions (REs) of STRs are difficult to diagnose, with low throughput methods such as locus-specific sizing or repeat primed PCR assays being most commonly performed ¹. Clinical testing is routinely available for SCAs caused by more common REs such as Friedreich's ataxia, SCA1, 2, 3, 6 and 7, but not rarer forms such as CANVAS, SCA 8, 10, 12, 17, 31, 36 and 37. Hence molecular diagnosis of ataxias due to REs, particularly less common REs such as those underlying SCA36, can be hard to obtain. In addition, current RE tests are expensive and time consuming, sometimes requiring international shipping of biospecimens. This has multiple negative outcomes, including uncertainty and a potential diagnostic odyssey for patients, while clinicians and health providers are unable to offer accurate prognosis, counselling and best clinical care.

Recent methodological advances in bioinformatics have made the simultaneous testing for all known REs through whole genome sequencing (WGS) feasible ². Additionally, multiple novel REs have recently been discovered in neurological disorders using WGS, including in epilepsy ³⁻⁶ and ataxia ⁷⁻⁹. Indeed, there is a growing recognition of the importance of REs and potential contribution to unsolved neurogenetic disease ¹⁰. This study demonstrated the potential utility of WGS for testing multiple SCA associated loci simultaneously.

In a recent study, we utilised WGS to discover a novel AAGGG RE in the gene replication factor 1 (*RFC1*) that causes cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome (CANVAS) ⁷. We provided a genetic CANVAS diagnosis to patients from 18 families in our Australian CANVAS cohort. Additionally, we used the WGS data to re-diagnose patients who tested negative for the *RFC1* RE with other forms of ataxia, including SCA3, also caused by a RE.

Here, we present a case study in which a three generation Australian pedigree with autosomal dominant ataxia was rapidly diagnosed with SCA36 using WGS-based bioinformatic approaches, and subsequently validated by two independent international service providers. SCA36 is a very rare ataxia with slow progression, and is characterized by adult-onset gait and appendicular ataxia, oculomotor abnormalities, cerebellar dysarthria and hyperreflexia. A definite clinical diagnosis of SCA36 is difficult due to overlap with other ataxias, and therefore targeted testing of this locus is not routinely considered. This issue is compounded by the fact that in Australia and many other countries there is no accredited diagnostic testing available for SCA36. A small number of international service providers offer single locus SCA36 testing, but the test is expensive, turnaround times can be long, and cannot provide the exact size of the RE. This study highlights that accredited diagnostic WGS, which is available in many countries, could provide an alternative single test to rapidly diagnose SCA36 and other unsolved ataxias, effectively addressing a previously unmet clinical need.

Methods

Institutional Ethics Committee approval was provided by the Royal Children's Hospital (Melbourne, HREC 28907), and written informed consent was obtained from all participants prior to study. Clinical details were collected from clinical assessments and review of medical records. Genomic DNA was isolated from blood using standard techniques and WGS was performed free for service by the Australian Genome Research Facility. Libraries were prepared using a PCR free kit (TruSeq) and sequenced using a Novaseq (Illumina). Alignment and haplotype calling were performed based on the GATK best practice pipeline. All samples were aligned to the hg19 reference genome using BWA-mem. Duplicate marking, local realignment, and recalibration were performed with GATK. Samples were screened for 12 ataxia STRs: SCA1,2,3,6,7,8,10,12,17,36, Friedreich's ataxia and CANVAS. RE detection tools exSTRa and ExpansionHunter were used, using default parameters, with additional parameters for ExpansionHunter: inclusion of off-target reads and read-depth of 30 and min-anchor-mapq of 20. Results were compared to 167 control WGS samples from the GTEx project.

Results

A large Australian family of European ancestry with seventeen individuals affected by ataxia over three generations was recruited to this study (Figure 1). Segregation is consistent with autosomal dominant inheritance, with apparently complete penetrance. At least 18 members of this family in 4 generations present with ataxia. Onset of symptoms is in mid adulthood and is slowly progressive. Lifespan is not significantly reduced with a number of affected individuals living into their 80s. A detailed neurological examination was undertaken on the three subjects and found that all displayed an ataxic gait, characterized by a broadened base of support, lateral veering, reduced walking speed, irregular foot placement, an increased stance phase and increased foot rotation angles^{11, 12}. Oculomotor abnormalities were consistent with cerebellar impairment and included saccadic horizontal and vertical visual pursuits¹³ and vestibulo-ocular reflex suppression¹⁴; and dysmetric saccades to target¹⁵. Cerebellar dysarthria with consequent reduction in speech intelligibility was also present^{16, 17}. Appendicular ataxia was seen in all four limbs and manifested by dysmetria^{18, 19} and intention tremor^{18, 20}. Global upper and lower limb hyperreflexia was also present on examination²¹.

WGS was performed for three affected individuals from the family (Figure 1) and the data was analysed for a pre-defined list of 12 candidate repeat expansions known to cause ataxia (SCA1,2,3,6,7,8,10,12,17,36, Friedreich's ataxia and CANVAS) using exSTRa²² and ExpansionHunter²³. This analysis identified the SCA36 RE in all three individuals, but none of the 167 controls. Based on evidence from the repeat read distributions plotted by exSTRa the RE was present in a heterozygous state in all affected individuals sequenced (Figure 2A). ExpansionHunter was used to estimate the size of the expanded allele determining a lower bound of ~800 repeat units (Figure 2B). This is a lower bound due to the limitations of sizing of very large expansions with short-read sequencing, with a known bias towards estimating fewer repeat motifs. This is a significant distinction as the pathogenic threshold for SCA36 has previously been described as greater than 650 repeats²⁴. Individuals with normal repeat size display a motif range of 1-12 repeat units. More precise sizing of SCA36 RE requires a Southern blot, however no such

Southern blot is currently available commercially to our knowledge due to the rarity of this RE. Visualisation of the locus in IGV confirms a large RE present in all three individuals (Figure 2C).

Subsequent to identification of SCA36, we performed confirmatory linkage analysis using genotypes extracted from the WGS data with LINKDATAGEN²⁵. While underpowered, this analysis identified 15 regions of identity by descent with LOD scores between 1 and 1.5 (data not shown). One of these regions (chr20:257608-7368304, LOD=1.5024, 20p13) overlapped SCA36, and also encompasses the genes for SCA23 (*PDYN*) and SCA35 (*TGM6*). A second linkage region on chromosome 4 intersects with the gene that causes SCA41. No potentially pathogenic sequence variants or RE were identified in these genes in the three affected individuals.

Clinical examination confirmed features consistent with SCA36. To confirm the diagnosis, molecular diagnostic SCA36 testing was ordered. As diagnostic testing is not currently available in Australia, diagnosis was sought through two independent international service providers (Fulgent and MNG Laboratories). Both returned a positive result, identifying one allele as greater than 70 repeats. However, only alleles >650 are considered full-penetrance and diagnostic of SCA36, while alleles between 15 and 650 repeats are considered variants of uncertain significance. Neither provider offers Southern blot or any other test to accurately size the RE.

Discussion

Here, we report for the first time that WGS can provide rapid and efficient diagnosis of SCA36. This is of significant clinical importance, given the difficulty and lack of availability of diagnostic testing for SCA36 worldwide, with affected individuals remaining underdiagnosed for this genetic mutation. Importantly, other than Southern blot, which is rarely used, no other test can identify >600 repeats for the SCA36 locus. While other methods such as Southern blot are still needed to determine the approximate size of the expansion, we demonstrate that WGS has the potential to offer a rapid and efficient method for to screen for ataxia-associated REs, such as SCA36.

SCA36 is a rare monogenic form of ataxia that is caused by an intronic GGCCTG hexanucleotide repeat expansion in *NOP56* (OMIM #614153). It was first identified in patients of Japanese ancestry, using linkage mapping in three unrelated families²⁴. Nine unrelated affected individuals were identified in a large Japanese ataxia cohort (n=251). These individuals shared a common haplotype, suggesting a single founder event for SCA36 in the Japanese population. Individuals with SCA36-mediated ataxia have since been identified in China, the US, Italy and Spain, with the latter country demonstrating a relatively high incidence of SCA36, owing to a founder effect²⁶. It appears likely that there are multiple founder events for SCA36 RE as has been observed for other repeat expansions, such as Huntington disease²⁷ and SCA3²⁸.

SCA36 is exceptionally rare - detected in 3.6% of patients in the initial Japanese study²⁴, and only 0.7% of unsolved ataxia patients in a US study (n=577)²⁹. Therefore, routine screening of ataxia patients for SCA36 using RP-PCR or by Southern blot is neither practical or cost effective. We propose that changing clinical practice to utilise WGS as a frontline test is a potentially cost-effective and efficient diagnostic pathway for individuals with a clinical diagnosis of ataxia. A

diagnosis obtained by WGS can then be independently validated by single locus RP-PCR or Southern blot test. This method allows for the screening of all known RE simultaneously while also allowing examination of point mutations in known ataxia genes. The WGS data can subsequently be used for novel gene discovery in unsolved cases.

The rapidity and ease of genetic diagnosis for this family with WGS-based RE detection analysis, after decades of genetic testing, will likely extrapolate to other rare REs as well. In the ataxias more broadly, numerous diagnostic procedures such as MRI, nerve conduction studies and cognitive testing are performed, in part to inform diagnostic genetic testing. However our experience, and globally, is that despite these extensive investigations, a diagnosis is only achieved in ~30% of cases³⁰⁻³². The diagnostic journey can be long (up to 20 years) and often unsuccessful. We strongly advocate the implementation of WGS for molecular diagnostic testing of individuals with a clinical diagnosis of ataxia. To facilitate these analyses we maintain up to date lists of known RE for all currently used bioinformatic RE detection tools. These can be obtained from <https://github.com/bahlolab/Bio-STR-exSTRa>.

Acknowledgements

We acknowledge contributions from Michael Hildebrand, Natasha Brown and Samuel Berkovic. P.J.L is supported by the Vincent Chiodo Foundation. M.B. was supported by an NHMRC Senior Research Fellowship (GNT1102971). D.J.S is supported by an NHMRC Early Career Fellowship (1129595). Whole genome sequencing costs were funded by Austin Health and the Victorian Medical Research Acceleration Fund through the Austin Health Undiagnosed Diseases Program. This work was supported in part by the Victorian Government's Operational Infrastructure Support Program and the NHMRC Independent Research Institute Infrastructure Support Scheme (IRISS).

Authors' roles

- 1) Research project: A. Conception, B. Organization, C. Execution;
- 2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique;
- 3) Manuscript: A. Writing of the first draft, B. Review and Critique.

HR: 1A,B,C, 2A,B,C, 3A,B.

DJS: 1B,C, 3B

KP: 1B,C, 3B

MW: 1B, 3B

JC: 1B, 3C

SMW: 1B, 3C

MBD: 1A,B,C, 2C, 3B

PJL: 1A,B,C, 2AC, 3B

MB: 1A, 2AC, 3B.

Financial disclosure: HR: none; DJS: none; KP: none; MW: none; JC: none; SMW: none; MBD: none; PJL: none; MB: none.


References


1. de Silva RN, Vallortigara J, Greenfield J, Hunt B, Giunti P, Hadjivassiliou M. Diagnosis and management of progressive ataxia in adults. *Pract Neurol* 2019;19(3):196-207.
2. Bahlo M, Bennett MF, Degorski P, Tankard RM, Delatycki MB, Lockhart PJ. Recent advances in the detection of repeat expansions with short-read next-generation sequencing. *F1000Res* 2018;7.
3. Ishiura H, Doi K, Mitsui J, et al. Expansions of intronic TTTCA and TTTTA repeats in benign adult familial myoclonic epilepsy. *Nat Genet* 2018;50(4):581-590.
4. Corbett MA, Kroes T, Veneziano L, et al. Intronic ATTTTC repeat expansions in STARD7 in familial adult myoclonic epilepsy linked to chromosome 2. *Nat Commun* 2019;10(1):4920.
5. Florian RT, Kraft F, Leita E, et al. Unstable TTTTA/TTTCA expansions in MARCH6 are associated with Familial Adult Myoclonic Epilepsy type 3. *Nat Commun* 2019;10(1):4919.
6. Yeetong P, Pongpanich M, Srichomthong C, et al. TTTCA repeat insertions in an intron of YEATS2 in benign adult familial myoclonic epilepsy type 4. *Brain* 2019;142(11):3360-3366.
7. Rafehi H, Szmulewicz DJ, Bennett MF, et al. Bioinformatics-Based Identification of Expanded Repeats: A Non-reference Intronic Pentamer Expansion in RFC1 Causes CANVAS. *Am J Hum Genet* 2019;105(1):151-165.
8. Cortese A, Simone R, Sullivan R, et al. Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia. *Nat Genet* 2019;51(4):649-658.
9. van Kuilenburg ABP, Tarailo-Graovac M, Richmond PA, et al. Glutaminase Deficiency Caused by Short Tandem Repeat Expansion in GLS. *N Engl J Med* 2019;380(15):1433-1441.

10. Lohmann K, Bruggemann N. Rediscovery of repeat expansions: Solving the unsolved cases. *Mov Disord* 2019;34(9):1300.
11. Stolze H, Klebe S, Petersen G, et al. Typical features of cerebellar ataxic gait. *J Neurol Neurosurg Psychiatry* 2002;73(3):310-312.
12. Buckley E, Mazza C, McNeill A. A systematic review of the gait characteristics associated with Cerebellar Ataxia. *Gait Posture* 2018;60:154-163.
13. Thier P, Ilg UJ. The neural basis of smooth-pursuit eye movements. *Curr Opin Neurobiol* 2005;15(6):645-652.
14. Chambers BR, Gresty MA. The relationship between disordered pursuit and vestibulo-ocular reflex suppression. *J Neurol Neurosurg Psychiatry* 1983;46(1):61-66.
15. Sharpe JA, Lo AW, Rabinovitch HE. Control of the saccadic and smooth pursuit systems after cerebral hemidecortication. *Brain* 1979;102(2):387-403.
16. Ackermann H, Vogel M, Petersen D, Poremba M. Speech deficits in ischaemic cerebellar lesions. *J Neurol* 1992;239(4):223-227.
17. Lechtenberg R, Gilman S. Speech disorders in cerebellar disease. *Ann Neurol* 1978;3(4):285-290.
18. Vilis T, Hore J. Central neural mechanisms contributing to cerebellar tremor produced by limb perturbations. *J Neurophysiol* 1980;43(2):279-291.
19. Manto M. Mechanisms of human cerebellar dysmetria: experimental evidence and current conceptual bases. *J Neuroeng Rehabil* 2009;6:10.
20. Hore J, Flament D. Evidence that a disordered servo-like mechanism contributes to tremor in movements during cerebellar dysfunction. *J Neurophysiol* 1986;56(1):123-136.

21. Paulson HL. The spinocerebellar ataxias. *J Neuroophthalmol* 2009;29(3):227-237.
22. Tankard RM, Bennett MF, Degorski P, Delatycki MB, Lockhart PJ, Bahlo M. Detecting Expansions of Tandem Repeats in Cohorts Sequenced with Short-Read Sequencing Data. *Am J Hum Genet* 2018;103(6):858-873.
23. Dolzhenko E, van Vugt J, Shaw RJ, et al. Detection of long repeat expansions from PCR-free whole-genome sequence data. *Genome Res* 2017;27(11):1895-1903.
24. Kobayashi H, Abe K, Matsuura T, et al. Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement. *Am J Hum Genet* 2011;89(1):121-130.
25. Bahlo M, Bromhead CJ. Generating linkage mapping files from Affymetrix SNP chip data. *Bioinformatics* 2009;25(15):1961-1962.
26. Arias M, Garcia-Murias M, Sobrido MJ. Spinocerebellar ataxia 36 (SCA36): <<Costa da Morte ataxia>>. *Neurologia* 2017;32(6):386-393.
27. Chao MJ, Kim KH, Shin JW, et al. Population-specific genetic modification of Huntington's disease in Venezuela. *PLoS Genet* 2018;14(5):e1007274.
28. Jayadev S, Michelson S, Lipe H, Bird T. Cambodian founder effect for spinocerebellar ataxia type 3 (Machado-Joseph disease). *J Neurol Sci* 2006;250(1-2):110-113.
29. Valera JM, Diaz T, Petty LE, et al. Prevalence of spinocerebellar ataxia 36 in a US population. *Neurol Genet* 2017;3(4):e174.
30. Coutelier M, Stevanin G, Brice A. Genetic landscape remodelling in spinocerebellar ataxias: the influence of next-generation sequencing. *J Neurol* 2015;262(10):2382-2395.

31. Galatolo D, Tessa A, Filla A, Santorelli FM. Clinical application of next generation sequencing in hereditary spinocerebellar ataxia: increasing the diagnostic yield and broadening the ataxia-spasticity spectrum. A retrospective analysis. *Neurogenetics* 2018;19(1):1-8.
32. Sullivan R, Yau WY, O'Connor E, Houlden H. Spinocerebellar ataxia: an update. *J Neurol* 2019;266(2):533-544.





COPYRIGHT TRANSFER AGREEMENT

Date: 06/03/2020

Contributor name: David J. Szmulewicz

Contributor address: Suite 1, level 2, 171 Victoria Pde, Fitzroy VIC 3065 Australia

Manuscript number: MDS-19-1513

Re: Manuscript entitled: Rapid diagnosis of SCA36 in a three-generation family using short-read whole genome sequencing data (the "Contribution")
for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic "preprints" of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor's nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor's own personal website, on the Contributor's internal intranet at Contributor's nonprofit organization or educational institution, or on a secure external website at the Contributor's nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor's non-profit organization or educational institution. Contributor shall not charge a fee for any

preprints, and Contributor's use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal's website, located at <http://www.interscience.Wiley.com>. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the "Accepted Version") is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: <http://www.wiley.com/go/funderstatement>.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: <http://www.wiley.com/go/funderstatement>. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

- a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
- b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-406074.html>. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution's repository after the following applicable embargo period has expired. See the following website for details: <http://olabout.wiley.com/WileyCDA/Section/id-817011.html>.

D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor's signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) ("patient identifiable content"), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)' physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 ("HIPAA") if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.

I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal's online author guidelines. Do not send in hard copies of these forms.

☒ Contributor-owned work		03/06/2020
	_____ Contributor's signature	_____ Date
	Dr David J. Szmulewicz	
	_____ Type or print name and title	
	_____ Co-Contributor's signature	_____ Date
	_____ Type or print name and title	

[] Company/Institution-owned
Work (made-for-hire in the
Course of employment)

Company or Institution (Employer-for-Hire)

Date

Authorized signature of Employer

Date

Contributor's signature

Date

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[] U.S. Government work

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[] U.K. Government work (Crown Copyright)

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[] Other

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Exhibit A**Financial Disclosure**

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: _____

Address: _____

Type of support: _____

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):


Name: _____


Address: _____

Type of support: _____

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY





mds_28105_figure 2.eps

COPYRIGHT TRANSFER AGREEMENT

Date: 06/03/2020

Contributor name: Haloom Rafehi

Contributor address: _____

Manuscript number: MDS-19-1513

Re: Manuscript entitled: Rapid diagnosis of SCA36 in a three-generation family using short-read whole genome sequencing data (the "Contribution")
for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic "preprints" of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor's nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor's own personal website, on the Contributor's internal intranet at Contributor's nonprofit organization or educational institution, or on a secure external website at the Contributor's nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor's non-profit organization or educational institution. Contributor shall not charge a fee for any

preprints, and Contributor's use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal's website, located at <http://www.interscience.Wiley.com>. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the "Accepted Version") is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: <http://www.wiley.com/go/funderstatement>.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: <http://www.wiley.com/go/funderstatement>. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

- a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
- b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-406074.html>. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution's repository after the following applicable embargo period has expired. See the following website for details: <http://olabout.wiley.com/WileyCDA/Section/id-817011.html>.

D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor's signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) ("patient identifiable content"), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)' physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 ("HIPAA") if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.

I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal's online author guidelines. Do not send in hard copies of these forms.

☒ Contributor-owned work		03/06/2020
	Contributor's signature	Date
	Dr Haloom Rafehi	
	Type or print name and title	
	_____ Co-Contributor's signature	_____ Date
	Type or print name and title	

[] Company/Institution-owned
Work (made-for-hire in the
Course of employment)

Company or Institution (Employer-for-Hire)

Date

Authorized signature of Employer

Date

Contributor's signature

Date

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[] **U.S. Government work**

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[] **U.K. Government work (Crown Copyright)**

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[] **Other**

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Exhibit A**Financial Disclosure**

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: _____

Address: _____

Type of support: _____

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: _____

Address: _____

Type of support: _____

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

COPYRIGHT TRANSFER AGREEMENT

Date: 06/03/2020

Contributor name: John Christodoulou

Contributor address: Murdoch Children's Research Institute, 50 Flemington Rd, Parkville, 3052, Vic, Australia

Manuscript number: MDS-19-1513

Re: Manuscript entitled: Rapid diagnosis of SCA36 in a three-generation family using short-read whole genome sequencing data (the "Contribution")
for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic "preprints" of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor's nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor's own personal website, on the Contributor's internal intranet at Contributor's nonprofit organization or educational institution, or on a secure external website at the Contributor's nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor's non-profit organization or educational institution. Contributor shall not charge a fee for any

preprints, and Contributor's use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal's website, located at <http://www.interscience.Wiley.com>. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the "Accepted Version") is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: <http://www.wiley.com/go/funderstatement>.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: <http://www.wiley.com/go/funderstatement>. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

- a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
- b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-406074.html>. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution's repository after the following applicable embargo period has expired. See the following website for details: <http://olabout.wiley.com/WileyCDA/Section/id-817011.html>.

D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor's signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) ("patient identifiable content"), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)' physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 ("HIPAA") if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.

I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal's online author guidelines. Do not send in hard copies of these forms.

[☒] Contributor-owned work



Contributor's signature

Prof. John Christodoulou

Type or print name and title

03/06/2020

Date

Co-Contributor's signature

Date

Type or print name and title

[] Company/Institution-owned
Work (made-for-hire in the
Course of employment)

Company or Institution (Employer-for-Hire)

Date

Authorized signature of Employer

Date

Contributor's signature

Date

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[] **U.S. Government work**

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[] **U.K. Government work (Crown Copyright)**

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[] **Other**

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Exhibit A**Financial Disclosure**

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: Victorian Government

Address: Melbourne

Type of support: Operational Infrastructure Support Program support

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: _____

Address: _____

Type of support: _____

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

COPYRIGHT TRANSFER AGREEMENT

Date: 06/03/2020

Contributor name: Kate Pope

Contributor address: 5th floor MCRI 50 Fleamington Rd
Parkville

Manuscript number: MDS-19-1513

Re: Manuscript entitled: Rapid diagnosis of SCA36 in a three-generation family using short-read whole genome sequencing data (the "Contribution")
for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic "preprints" of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor's nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor's own personal website, on the Contributor's internal intranet at Contributor's nonprofit organization or educational institution, or on a secure external website at the Contributor's nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor's non-profit organization or educational institution. Contributor shall not charge a fee for any

preprints, and Contributor's use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal's website, located at <http://www.interscience.Wiley.com>. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the "Accepted Version") is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: <http://www.wiley.com/go/funderstatement>.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: <http://www.wiley.com/go/funderstatement>. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

- a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
- b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-406074.html>. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution's repository after the following applicable embargo period has expired. See the following website for details: <http://olabout.wiley.com/WileyCDA/Section/id-817011.html>.

D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor's signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) ("patient identifiable content"), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)' physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 ("HIPAA") if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.

I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal's online author guidelines. Do not send in hard copies of these forms.

☒ Contributor-owned work



Contributor's signature

03/06/2020

Date

Kate Pope

Type or print name and title

Co-Contributor's signature

Date

Type or print name and title

[] Company/Institution-owned
Work (made-for-hire in the
Course of employment)

Company or Institution (Employer-for-Hire)

Date

Authorized signature of Employer

Date

Contributor's signature

Date

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[] **U.S. Government work**

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[] **U.K. Government work (Crown Copyright)**

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[] **Other**

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Exhibit A

Financial Disclosure

Not

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: _____

Address: _____

Type of support: _____

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: _____

Address: _____

Type of support: _____

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

COPYRIGHT TRANSFER AGREEMENT

Date: 06/03/2020

Contributor name: Martin B Delatycki

Contributor address: Murdoch Children's Research Institute

Manuscript number: MDS-19-1513

Re: Manuscript entitled: Rapid diagnosis of SCA36 in a three-generation

family using short-read whole genome (the "Contribution")

sequencing data
for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic "preprints" of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor's nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor's own personal website, on the Contributor's internal intranet at Contributor's nonprofit organization or educational institution, or on a secure external website at the Contributor's nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor's non-profit organization or educational institution. Contributor shall not charge a fee for any

preprints, and Contributor's use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal's website, located at <http://www.interscience.Wiley.com>. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the "Accepted Version") is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: <http://www.wiley.com/go/funderstatement>.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: <http://www.wiley.com/go/funderstatement>. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

- a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
- b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-406074.html>. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution's repository after the following applicable embargo period has expired. See the following website for details: <http://olabout.wiley.com/WileyCDA/Section/id-817011.html>.

D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor's signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) ("patient identifiable content"), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)' physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 ("HIPAA") if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.

I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal's online author guidelines. Do not send in hard copies of these forms.

☒ Contributor-owned work

Contributor's signature

Martín B Delatycki

Type or print name and title

03/06/2020

Date

Co-Contributor's signature

Date

Type or print name and title

[] Company/Institution-owned Work (made-for-hire in the Course of employment)		
	Company or Institution (Employer-for-Hire)	Date
	Authorized signature of Employer	Date
	Contributor's signature	Date
	Type or print name and title	

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[] **U.S. Government work**

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[] **U.K. Government work (Crown Copyright)**

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[] **Other**

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Exhibit A

Financial Disclosure

Nil

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: _____

Address: _____

Type of support: _____

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: _____

Address: _____

Type of support: _____

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

COPYRIGHT TRANSFER AGREEMENT

Date: 06/03/2020

Contributor name: Mathew Wallis
~~Tasmanian Clinical Genetics Service, c/o Royal Hobart Hospital, GPO Box~~

Contributor address: 1061, Hobart TAS 7001

Manuscript number: MDS-19-1513

Re: Manuscript entitled: Rapid diagnosis of SCA36 in a three-generation family using short-read whole genome sequencing data (the "Contribution")
for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic "preprints" of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor's nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor's own personal website, on the Contributor's internal intranet at Contributor's nonprofit organization or educational institution, or on a secure external website at the Contributor's nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor's non-profit organization or educational institution. Contributor shall not charge a fee for any

preprints, and Contributor's use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal's website, located at <http://www.interscience.Wiley.com>. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the "Accepted Version") is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: <http://www.wiley.com/go/funderstatement>.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: <http://www.wiley.com/go/funderstatement>. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

- a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
- b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-406074.html>. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution's repository after the following applicable embargo period has expired. See the following website for details: <http://olabout.wiley.com/WileyCDA/Section/id-817011.html>.

D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor's signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) ("patient identifiable content"), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)' physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 ("HIPAA") if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.

I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal's online author guidelines. Do not send in hard copies of these forms.

[☒] Contributor-owned work



03/06/2020

Contributor's signature

Date

Dr Mathew Wallis

Type or print name and title

Co-Contributor's signature

Date

Type or print name and title

[] Company/Institution-owned
Work (made-for-hire in the
Course of employment)

Company or Institution (Employer-for-Hire)

Date

Authorized signature of Employer

Date

Contributor's signature

Date

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[] U.S. Government work

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[] U.K. Government work (Crown Copyright)

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[] Other

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Exhibit A**Financial Disclosure**

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: _____

Address: _____

Type of support: _____

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: _____

Address: _____

Type of support: _____

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

COPYRIGHT TRANSFER AGREEMENT

Date: 06/03/2020

Contributor name: Melanie Bahlo

Contributor address: Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville 3052 VIC, Australia

Manuscript number: MDS-19-1513

Re: Manuscript entitled: Rapid diagnosis of SCA36 in a three-generation family using short-read whole genome sequencing data (the "Contribution")
for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic "preprints" of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor's nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor's own personal website, on the Contributor's internal intranet at Contributor's nonprofit organization or educational institution, or on a secure external website at the Contributor's nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor's non-profit organization or educational institution. Contributor shall not charge a fee for any

preprints, and Contributor's use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal's website, located at <http://www.interscience.Wiley.com>. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the "Accepted Version") is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: <http://www.wiley.com/go/funderstatement>.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: <http://www.wiley.com/go/funderstatement>. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

- a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
- b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-406074.html>. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution's repository after the following applicable embargo period has expired. See the following website for details: <http://olabout.wiley.com/WileyCDA/Section/id-817011.html>.

D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor's signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) ("patient identifiable content"), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)' physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 ("HIPAA") if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.

I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal's online author guidelines. Do not send in hard copies of these forms.

[☒] Contributor-owned work	<u>Melanie Bahlo</u>	<u>03/06/2020</u>
	Contributor's signature	Date
	<u>Professor Melanie Bahlo</u>	
	Type or print name and title	
	<u></u>	<u></u>
	Co-Contributor's signature	Date
	<u></u>	<u></u>
	Type or print name and title	

[] Company/Institution-owned
Work (made-for-hire in the
Course of employment)

Company or Institution (Employer-for-Hire)

Date

Authorized signature of Employer

Date

Contributor's signature

Date

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[] **U.S. Government work**

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[] **U.K. Government work (Crown Copyright)**

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[] **Other**

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: Melanie Bahlo

Address: The Walter and Eliza Hall Institute of Medical Research

Type of support: Research Fellowship (National Health and Medical Research Council of Australia)

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: Melanie Bahlo

Address: The Walter and Eliza Hall Institute of Medical Research

Type of support: International Center of Excellence in Malaria Research

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: _____

Address: _____

Type of support: _

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: Melanie Bahlo

Address: The Walter and Eliza Hall Institute of Medical Research

Type of support: Project Grant (National Health and Medical Research Council of Australia)

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

Exhibit A**Financial Disclosure**

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: _____

Address: _____

Type of support: _

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: Melanie Bahlo _____

Address: The Walter and Eliza Hall Institute of Medical Research

Type of support: Victorian Medical Research Acceleration Fund grant

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: _____

Address: _____

Type of support: _

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: Melanie Bahlo

Address: The Walter and Eliza Hall Institute of Medical Research

Type of support: CureKids (New Zealand)

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: _____

Address: _____

Type of support:

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: Melanie Bahlo

Address: The Walter and Eliza Hall Institute of Medical Research

Type of support: Complex Neurological and Neurodegenerative Disease Melbourne Genomics Health

Alliance Flagship

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

COPYRIGHT TRANSFER AGREEMENT

Date: 06/03/2020

Contributor name: Paul J Lockhart

Contributor address: MCRI, Level 5, 50 Flemington Rd, Pakville, Australia, 3052

Manuscript number: MDS-19-1513
Rapid diagnosis of SCA36 in a three-generation

Re: Manuscript entitled: family using short-read whole genome (the "Contribution")
sequencing data

for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic "preprints" of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor's nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor's own personal website, on the Contributor's internal intranet at Contributor's nonprofit organization or educational institution, or on a secure external website at the Contributor's nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor's non-profit organization or educational institution. Contributor shall not charge a fee for any

preprints, and Contributor's use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal's website, located at <http://www.interscience.Wiley.com>. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the "Accepted Version") is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: <http://www.wiley.com/go/funderstatement>.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: <http://www.wiley.com/go/funderstatement>. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

- a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
- b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-406074.html>. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution's repository after the following applicable embargo period has expired. See the following website for details: <http://olabout.wiley.com/WileyCDA/Section/id-817011.html>.

D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor's signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) ("patient identifiable content"), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)' physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 ("HIPAA") if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.

I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal's online author guidelines. Do not send in hard copies of these forms.

☒ Contributor-owned work		03/06/2020
	Contributor's signature	Date
	Dr Paul J Lockhart	
	Type or print name and title	
	_____ Co-Contributor's signature	_____ Date
	_____ Type or print name and title	

[] Company/Institution-owned
Work (made-for-hire in the
Course of employment)

Company or Institution (Employer-for-Hire)

Date

Authorized signature of Employer

Date

Contributor's signature

Date

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[] **U.S. Government work**

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[] **U.K. Government work (Crown Copyright)**

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[] **Other**

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Exhibit A**Financial Disclosure**

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: _____

Address: _____

Type of support: _____

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: Paul Lockhart

Address: MCRI, Level 5, 50 Flemington Rd, Parkville, Australia, 3052

Type of support: Paul J Lockhart received funding from the National Health and Medical Research Council (GNT1128933 and GNT1161549) and is supported by the Vincent Chiodo Foundation.

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

Rapid diagnosis of SCA36 in a three-generation family using short-read whole genome sequencing data

Haloom Rafehi PhD^{1,2,3}, David J. Szmulewicz MBBS FRACP PhD^{4,5}, Kate Pope BSc Grad Dip Gen Couns⁶, Mathew Wallis BSc MBBS FRACP^{7,8}, John Christodoulou MBBS FRACP PhD^{9,10}, Susan M White MBBS FRACP^{10,11,12}, Martin B Delatycki MBBS FRACP PhD^{6,10,11}, Paul J Lockhart PhD^{6,10}, Melanie Bahlo PhD^{*1,2}

1. Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
2. Department of Medical Biology, University of Melbourne, Melbourne, Australia
3. Epilepsy Research Centre, University of Melbourne, Austin Health, Melbourne, Australia
4. Cerebellar Ataxia Clinic, Neuroscience Department, Alfred Health, Melbourne, VIC 3004, Australia;
5. Balance Disorders and Ataxia Service, Royal Victorian Eye & Ear Hospital, East Melbourne, VIC 3002, Australia
6. Bruce Lefroy Centre for Genetic Health Research, Murdoch Children's Research Institute, 50 Flemington Road Parkville, Victoria, 3052, Australia
7. Tasmanian Clinical Genetics Service, Tasmanian Health Service, Tasmania, Australia
8. School of Medicine and Menzies Institute for Medical Research, University of Tasmania, Tasmania, Australia
9. Brain and Mitochondrial Research Group, Murdoch Children's Research Institute, 50 Flemington Road Parkville, Victoria, 3052, Australia
10. Department of Pediatrics, The University of Melbourne, 30 Royal Parade Parkville, Victoria, 3052, Australia
11. Victorian Clinical Genetics Services, 50 Flemington Road Parkville, Victoria, 3052, Australia
12. Murdoch Children's Research Institute, 50 Flemington Road Parkville, Victoria, 3052, Australia

*Corresponding author:

Prof. Melanie Bahlo
The Walter and Eliza Hall Institute of Medical Research
1G Royal Parade, Parkville
Victoria 3052
Australia
bahlo@wehi.edu.au

Word count (main text): 1736.

Running title: SCA36 diagnosis by whole genome sequencing

Keywords: ataxia, repeat expansions, short tandem repeats, diagnosis, exSTRa

Financial disclosure/conflicts of interest: Nothing to report.

Funding sources for study: The funding bodies had no role in the design, analysis, interpretation or reporting of results.

Abstract

Background: Spinocerebellar ataxias (SCA) are often caused by expansions of short tandem repeats (STRs). Recent methodological advances have made repeat expansion (RE) detection with whole genome sequencing (WGS) feasible.

Objectives: To determine the genetic basis of ataxia in a multigenerational Australian pedigree, with autosomal dominant inheritance.

Methods and Results: WGS was performed on three affected relatives. The sequence data was screened for known pathogenic REs using two repeat expansion detection tools: exSTRa and ExpansionHunter. This screen provided a clear and rapid diagnosis (<five days from receiving the sequencing data) of SCA36, a rare form of ataxia caused by an intronic GGCCTG RE in *NOP56*.

Conclusions: The diagnosis of rare ataxias caused by REs is highly feasible and cost effective with WGS. We propose that WGS could potentially be implemented as the frontline, cost effective methodology for molecular testing of individuals with a clinical diagnosis of ataxia.

Introduction

Spinocerebellar ataxias (SCA) comprise a group of rare, progressive neurological disorders that can be caused by deleterious coding-sequence point mutations or pathogenic expansions of short tandem repeats (STRs). Ataxias caused by repeat expansions (REs) of STRs are difficult to diagnose, with low throughput methods such as locus-specific sizing or repeat primed PCR assays being most commonly performed¹. Clinical testing is routinely available for SCAs caused by more common REs such as Friedreich's ataxia, SCA1, 2, 3, 6 and 7, but not rarer forms such as CANVAS, SCA 8, 10, 12, 17, 31, 36 and 37. Hence molecular diagnosis of ataxias due to REs, particularly less common REs such as those underlying SCA36, can be hard to obtain. In addition, current RE tests are expensive and time consuming, sometimes requiring international shipping of biospecimens. This has multiple negative outcomes, including uncertainty and a potential diagnostic odyssey for patients, while clinicians and health providers are unable to offer accurate prognosis, counselling and best clinical care.

Recent methodological advances in bioinformatics have made the simultaneous testing for all known REs through whole genome sequencing (WGS) feasible². Additionally, multiple novel REs have recently been discovered in neurological disorders using WGS, including in epilepsy³⁻⁶ and ataxia⁷⁻⁹. Indeed, there is a growing recognition of the importance of REs and potential contribution to unsolved neurogenetic disease¹⁰. This study demonstrated the potential utility of WGS for testing multiple SCA associated loci simultaneously.

In a recent study, we utilised WGS to discover a novel AAGGG RE in the gene replication factor 1 (*RFC1*) that causes cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome (CANVAS)⁷. We provided a genetic CANVAS diagnosis to patients from 18 families in our Australian CANVAS cohort. Additionally, we used the WGS data to re-diagnose patients who tested negative for the *RFC1* RE with other forms of ataxia, including SCA3, also caused by a RE.

Here, we present a case study in which a three generation Australian pedigree with autosomal dominant ataxia was rapidly diagnosed with SCA36 using WGS-based bioinformatic approaches, and subsequently validated by two independent international service providers. SCA36 is a very rare ataxia with slow progression, and is characterized by adult-onset gait and appendicular ataxia, oculomotor abnormalities, cerebellar dysarthria and hyperreflexia. A definite clinical diagnosis of SCA36 is difficult due to overlap with other ataxias, and therefore targeted testing of this locus is not routinely considered. This issue is compounded by the fact that in Australia and many other countries there is no accredited diagnostic testing available for SCA36. A small number of international service providers offer single locus SCA36 testing, but the test is expensive, turnaround times can be long, and cannot provide the exact size of the RE. This study highlights that accredited diagnostic WGS, which is available in many countries, could provide an alternative single test to rapidly diagnose SCA36 and other unsolved ataxias, effectively addressing a previously unmet clinical need.

Methods

Institutional Ethics Committee approval was provided by the Royal Children's Hospital (Melbourne, HREC 28907), and written informed consent was obtained from all participants prior to study. Clinical details were collected from clinical assessments and review of medical records. Genomic DNA was isolated from blood using standard techniques and WGS was performed for service by the Australian Genome Research Facility. Libraries were prepared using a PCR free kit (TruSeq) and sequenced using a Novaseq (Illumina). Alignment and haplotype calling

were performed based on the GATK best practice pipeline. All samples were aligned to the hg19 reference genome using BWA-mem. Duplicate marking, local realignment, and recalibration were performed with GATK. Samples were screened for 12 ataxia STRs: SCA1,2,3,6,7,8,10,12,17,36, Friedreich's ataxia and CANVAS. RE detection tools exSTRA and ExpansionHunter were used, using default parameters, with additional parameters for ExpansionHunter: inclusion of off-target reads and read-depth of 30 and min-anchor-mapq of 20. Results were compared to 167 control WGS samples from the GTEx project.

Results

A large Australian family of European ancestry with seventeen individuals affected by ataxia over three generations was recruited to this study (Figure 1). Segregation is consistent with autosomal dominant inheritance, with apparently complete penetrance. At least 18 members of this family in 4 generations present with ataxia. Onset of symptoms is in mid adulthood and is slowly progressive. Lifespan is not significantly reduced with a number of affected individuals living into their 80s. A detailed neurological examination was undertaken on the three subjects and found that all displayed an ataxic gait, characterized by a broadened base of support, lateral veering, reduced walking speed, irregular foot placement, an increased stance phase and increased foot rotation angles^{11, 12}. Oculomotor abnormalities were consistent with cerebellar impairment and included saccadic horizontal and vertical visual pursuits¹³ and vestibulo-ocular reflex suppression¹⁴; and dysmetric saccades to target¹⁵. Cerebellar dysarthria with consequent reduction in speech intelligibility was also present^{16, 17}. Appendicular ataxia was seen in all four limbs and manifested by dysmetria^{18, 19} and intention tremor^{18, 20}. Global upper and lower limb hyperreflexia was also present on examination²¹.

WGS was performed for three affected individuals from the family (Figure 1) and the data was analysed for a pre-defined list of 12 candidate repeat expansions known to cause ataxia (SCA1,2,3,6,7,8,10,12,17,36, Friedreich's ataxia and CANVAS) using exSTRA²² and ExpansionHunter²³. This analysis identified the SCA36 RE in all three individuals, but none of the 167 controls. Based on evidence from the repeat read distributions plotted by exSTRA the RE was present in a heterozygous state in all affected individuals sequenced (Figure 2A). ExpansionHunter was used to estimate the size of the expanded allele determining a lower bound of ~800 repeat units (Figure 2B). This is a lower bound due to the limitations of sizing of very large expansions with short-read sequencing, with a known bias towards estimating fewer repeat motifs. This is a significant distinction as the pathogenic threshold for SCA36 has previously been described as greater than 650 repeats²⁴. Individuals with normal repeat size display a motif range of 1-12 repeat units. More precise sizing of SCA36 RE requires a Southern blot, however no such Southern blot is currently available commercially to our knowledge due to the rarity of this RE. Visualisation of the locus in IGV confirms a large RE present in all three individuals (Figure 2C).

Subsequent to identification of SCA36, we performed confirmatory linkage analysis using genotypes extracted from the WGS data with LINKDATAGEN²⁵. While underpowered, this analysis identified 15 regions of identity by descent with LOD scores between 1 and 1.5 (data not shown). One of these regions (chr20:257608-7368304, LOD=1.5024, 20p13) overlapped SCA36, and also encompasses the genes for SCA23 (*PDYN*) and SCA35 (*TGM6*). A second linkage region on chromosome 4 intersects with the gene that causes SCA41. No potentially pathogenic sequence variants or RE were identified in these genes in the three affected individuals.

Clinical examination confirmed features consistent with SCA36. To confirm the diagnosis, molecular diagnostic SCA36 testing was ordered. As diagnostic testing is not currently available in Australia, diagnosis was sought through two independent international service providers

(Fulgent and MNG Laboratories). Both returned a positive result, identifying one allele as greater than 70 repeats. However, only alleles >650 are considered full-penetrance and diagnostic of SCA36, while alleles between 15 and 650 repeats are considered variants of uncertain significance. Neither provider offers Southern blot or any other test to accurately size the RE.

Discussion

Here, we report for the first time that WGS can provide rapid and efficient diagnosis of SCA36. This is of significant clinical importance, given the difficulty and lack of availability of diagnostic testing for SCA36 worldwide, with affected individuals remaining underdiagnosed for this genetic mutation. Importantly, other than Southern blot, which is rarely used, no other test can identify >600 repeats for the SCA36 locus. While other methods such as Southern blot are still needed to determine the approximate size of the expansion, we demonstrate that WGS has the potential to offer a rapid and efficient method for to screen for ataxia-associated REs, such as SCA36.

SCA36 is a rare monogenic form of ataxia that is caused by an intronic GGCCTG hexanucleotide repeat expansion in *NOP56* (OMIM #614153). It was first identified in patients of Japanese ancestry, using linkage mapping in three unrelated families²⁴. Nine unrelated affected individuals were identified in a large Japanese ataxia cohort (n=251). These individuals shared a common haplotype, suggesting a single founder event for SCA36 in the Japanese population. Individuals with SCA36-mediated ataxia have since been identified in China, the US, Italy and Spain, with the latter country demonstrating a relatively high incidence of SCA36, owing to a founder effect²⁶. It appears likely that there are multiple founder events for SCA36 RE as has been observed for other repeat expansions, such as Huntington disease²⁷ and SCA3²⁸.

SCA36 is exceptionally rare - detected in 3.6% of patients in the initial Japanese study²⁴, and only 0.7% of unsolved ataxia patients in a US study (n=577)²⁹. Therefore, routine screening of ataxia patients for SCA36 using RP-PCR or by Southern blot is neither practical or cost effective. We propose that changing clinical practice to utilise WGS as a frontline test is a potentially cost-effective and efficient diagnostic pathway for individuals with a clinical diagnosis of ataxia. A diagnosis obtained by WGS can then be independently validated by single locus RP-PCR or Southern blot test. This method allows for the screening of all known RE simultaneously while also allowing examination of point mutations in known ataxia genes. The WGS data can subsequently be used for novel gene discovery in unsolved cases.

The rapidity and ease of genetic diagnosis for this family with WGS-based RE detection analysis, after decades of genetic testing, will likely extrapolate to other rare REs as well. In the ataxias more broadly, numerous diagnostic procedures such as MRI, nerve conduction studies and cognitive testing are performed, in part to inform diagnostic genetic testing. However our experience, and globally, is that despite these extensive investigations, a diagnosis is only achieved in ~30% of cases³⁰⁻³². The diagnostic journey can be long (up to 20 years) and often unsuccessful. We strongly advocate the implementation of WGS for molecular diagnostic testing of individuals with a clinical diagnosis of ataxia. To facilitate these analyses we maintain up to date lists of known RE for all currently used bioinformatic RE detection tools. These can be obtained from <https://github.com/bahlolab/Bio-STR-exSTRA>.

Acknowledgements

We acknowledge contributions from Michael Hildebrand, Natasha Brown and Samuel Berkovic. P.J.L is supported by the Vincent Chiodo Foundation. M.B. was supported by an NHMRC Senior Research Fellowship (GNT1102971). D.J.S is supported by an NHMRC Early Career Fellowship

(1129595). Whole genome sequencing costs were funded by Austin Health and the Victorian Medical Research Acceleration Fund through the Austin Health Undiagnosed Diseases Program. This work was supported in part by the Victorian Government's Operational Infrastructure Support Program and the NHMRC Independent Research Institute Infrastructure Support Scheme (IRIIS).

Authors' roles

- 1) Research project: A. Conception, B. Organization, C. Execution;
- 2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique;
- 3) Manuscript: A. Writing of the first draft, B. Review and Critique.

HR: 1A,B,C, 2A,B,C, 3A,B.

DJS: 1B,C, 3B

KP: 1B,C, 3B

MW:1B, 3B

JC: 1B, 3C

SMW: 1B, 3C

MBD: 1A,B,C, 2C, 3B

PJL: 1A,B,C, 2AC, 3B

MB: 1A, 2AC, 3B.

Financial disclosure: HR: none; DJS: none; KP: none; MW: none; JC: none; SMW: none; MBD: none; PJL: none; MB: none.

References

1. de Silva RN, Vallortigara J, Greenfield J, Hunt B, Giunti P, Hadjivassiliou M. Diagnosis and management of progressive ataxia in adults. *Pract Neurol* 2019;19(3):196-207.
2. Bahlo M, Bennett MF, Degorski P, Tankard RM, Delatycki MB, Lockhart PJ. Recent advances in the detection of repeat expansions with short-read next-generation sequencing. *F1000Res* 2018;7.
3. Ishiura H, Doi K, Mitsui J, et al. Expansions of intronic TTTCA and TTTTA repeats in benign adult familial myoclonic epilepsy. *Nat Genet* 2018;50(4):581-590.
4. Corbett MA, Kroes T, Veneziano L, et al. Intronic ATTTTC repeat expansions in STARD7 in familial adult myoclonic epilepsy linked to chromosome 2. *Nat Commun* 2019;10(1):4920.
5. Florian RT, Kraft F, Leita E, et al. Unstable TTTTA/TTTCA expansions in MARCH6 are associated with Familial Adult Myoclonic Epilepsy type 3. *Nat Commun* 2019;10(1):4919.
6. Yeetong P, Pongpanich M, Srichomthong C, et al. TTTCA repeat insertions in an intron of YEATS2 in benign adult familial myoclonic epilepsy type 4. *Brain* 2019;142(11):3360-3366.
7. Rafehi H, Szmulewicz DJ, Bennett MF, et al. Bioinformatics-Based Identification of Expanded Repeats: A Non-reference Intronic Pentamer Expansion in RFC1 Causes CANVAS. *Am J Hum Genet* 2019;105(1):151-165.
8. Cortese A, Simone R, Sullivan R, et al. Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia. *Nat Genet* 2019;51(4):649-658.
9. van Kuilenburg ABP, Tarailo-Graovac M, Richmond PA, et al. Glutaminase Deficiency Caused by Short Tandem Repeat Expansion in GLS. *N Engl J Med* 2019;380(15):1433-1441.
10. Lohmann K, Bruggemann N. Rediscovery of repeat expansions: Solving the unsolved cases. *Mov Disord* 2019;34(9):1300.
11. Stolze H, Klebe S, Petersen G, et al. Typical features of cerebellar ataxic gait. *J Neurol Neurosurg Psychiatry* 2002;73(3):310-312.

12. Buckley E, Mazza C, McNeill A. A systematic review of the gait characteristics associated with Cerebellar Ataxia. *Gait Posture* 2018;60:154-163.
13. Thier P, Ilg UJ. The neural basis of smooth-pursuit eye movements. *Curr Opin Neurobiol* 2005;15(6):645-652.
14. Chambers BR, Gresty MA. The relationship between disordered pursuit and vestibulo-ocular reflex suppression. *J Neurol Neurosurg Psychiatry* 1983;46(1):61-66.
15. Sharpe JA, Lo AW, Rabinovitch HE. Control of the saccadic and smooth pursuit systems after cerebral hemidecortication. *Brain* 1979;102(2):387-403.
16. Ackermann H, Vogel M, Petersen D, Poremba M. Speech deficits in ischaemic cerebellar lesions. *J Neurol* 1992;239(4):223-227.
17. Lechtenberg R, Gilman S. Speech disorders in cerebellar disease. *Ann Neurol* 1978;3(4):285-290.
18. Vilis T, Hore J. Central neural mechanisms contributing to cerebellar tremor produced by limb perturbations. *J Neurophysiol* 1980;43(2):279-291.
19. Manto M. Mechanisms of human cerebellar dysmetria: experimental evidence and current conceptual bases. *J Neuroeng Rehabil* 2009;6:10.
20. Hore J, Flament D. Evidence that a disordered servo-like mechanism contributes to tremor in movements during cerebellar dysfunction. *J Neurophysiol* 1986;56(1):123-136.
21. Paulson HL. The spinocerebellar ataxias. *J Neuroophthalmol* 2009;29(3):227-237.
22. Tankard RM, Bennett MF, Degorski P, Delatycki MB, Lockhart PJ, Bahlo M. Detecting Expansions of Tandem Repeats in Cohorts Sequenced with Short-Read Sequencing Data. *Am J Hum Genet* 2018;103(6):858-873.
23. Dolzhenko E, van Vugt J, Shaw RJ, et al. Detection of long repeat expansions from PCR-free whole-genome sequence data. *Genome Res* 2017;27(11):1895-1903.

24. Kobayashi H, Abe K, Matsuura T, et al. Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement. *Am J Hum Genet* 2011;89(1):121-130.
25. Bahlo M, Bromhead CJ. Generating linkage mapping files from Affymetrix SNP chip data. *Bioinformatics* 2009;25(15):1961-1962.
26. Arias M, Garcia-Murias M, Sobrido MJ. Spinocerebellar ataxia 36 (SCA36): <<Costa da Morte ataxia>>. *Neurologia* 2017;32(6):386-393.
27. Chao MJ, Kim KH, Shin JW, et al. Population-specific genetic modification of Huntington's disease in Venezuela. *PLoS Genet* 2018;14(5):e1007274.
28. Jayadev S, Michelson S, Lipe H, Bird T. Cambodian founder effect for spinocerebellar ataxia type 3 (Machado-Joseph disease). *J Neurol Sci* 2006;250(1-2):110-113.
29. Valera JM, Diaz T, Petty LE, et al. Prevalence of spinocerebellar ataxia 36 in a US population. *Neurol Genet* 2017;3(4):e174.
30. Coutelier M, Stevanin G, Brice A. Genetic landscape remodelling in spinocerebellar ataxias: the influence of next-generation sequencing. *J Neurol* 2015;262(10):2382-2395.
31. Galatolo D, Tessa A, Filla A, Santorelli FM. Clinical application of next generation sequencing in hereditary spinocerebellar ataxia: increasing the diagnostic yield and broadening the ataxia-spasticity spectrum. A retrospective analysis. *Neurogenetics* 2018;19(1):1-8.
32. Sullivan R, Yau WY, O'Connor E, Houlden H. Spinocerebellar ataxia: an update. *J Neurol* 2019;266(2):533-544.

COPYRIGHT TRANSFER AGREEMENT

Date: 06/03/2020

Contributor name: Susan M White

Contributor address: Victorian Clinical Genetics Service

Manuscript number: MDS-19-1513

Re: Manuscript entitled: Rapid diagnosis of SCA36 in a three-generation family using short-read whole genome sequencing data (the "Contribution")
for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic "preprints" of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor's nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor's own personal website, on the Contributor's internal intranet at Contributor's nonprofit organization or educational institution, or on a secure external website at the Contributor's nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor's non-profit organization or educational institution. Contributor shall not charge a fee for any

preprints, and Contributor's use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserv, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal's website, located at <http://www.interscience.Wiley.com>. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the "Accepted Version") is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: <http://www.wiley.com/go/funderstatement>.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: <http://www.wiley.com/go/funderstatement>. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

- a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
- b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-406074.html>. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution's repository after the following applicable embargo period has expired. See the following website for details: <http://olabout.wiley.com/WileyCDA/Section/id-817011.html>.

D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor's signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) ("patient identifiable content"), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)' physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 ("HIPAA") if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.

I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.


J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal's online author guidelines. Do not send in hard copies of these forms.

☒ Contributor-owned work



03/06/2020

Contributor's signature

Date

Susan M White

Type or print name and title

Co-Contributor's signature

Date

Type or print name and title

[] Company/Institution-owned
Work (made-for-hire in the
Course of employment)

Company or Institution (Employer-for-Hire)

Date

Authorized signature of Employer

Date

Contributor's signature

Date

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[] **U.S. Government work**

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[] **U.K. Government work (Crown Copyright)**

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[X] **Other**

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Exhibit A
Financial Disclosure

Nil

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: _____

Address: _____

Type of support: _____

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: _____

Address: _____

Type of support: _____

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY